The BioInsights Podcast
The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.
The BioInsights Podcast
Making the switch from autologous to allogeneic cell therapy
•
Elena Matsa & Andy Holt
•
Season 1
•
Episode 13
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
To set the scene, could you firstly tell me a bit about your backgrounds, and your current work?
What role do you predict induced pluripotent stem cells (iPSCs) will play in the future of cell therapy?
What are the key benefits of autologous versus allogeneic cell therapies?
What do you see as the biggest obstacles to successful iPSC-based allogeneic cell therapy development – and how can they be addressed?
What are the most important considerations for developing a successful cell therapy manufacturing process?
What is your key advice for making the change from autologous to allogeneic cell therapy development a practical reality?